Importantly, because maternal BMI is potentially modifiable (at least in the short term) through diet, exercise [51], and/or a glucagon-like peptide-1 receptor agonist [52] (e.g., semaglutide), this work holds promise in contributing to an improved understanding of plausible intervention targets to prevent or attenuate the intergenerational transfer of obesity risk. Here, GLP1R is linked to obesity disorder.